Biasca, Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ROCHE today announced the signing of a licensing agreement, granting HELSINN HEALTHCARE the worldwide rights for the patented, phase II product, NETUPITANT. Netupitant is a potent and selective NK-1 receptor antagonist, developed as NKE by Roche, for the prevention of chemotherapy-induced nausea and vomiting (CINV). "We are ...
DUBLIN, IRELAND, May 11th, 2005 - HELSINN BIREX THERAPEUTICS LTD, one of the Irish companies of the Swiss pharmaceutical group Helsinn Healthcare SA, announced today that the company received the first delivery of ALOXI" (palonosetron hydrochloride) from Helsinn Birex Pharmaceuticals LTD, Dublin, on 9th May 2005 ...
Biasca, Switzerland (ots) - Helsinn Chemicals SA and Helsinn Advanced Synthesis SA have successfully passed a re-certification audit of its ISO14001 Environmental Management System. The audit by SGS took place on May 2nd and 3rd 2005. In parallel, Helsinn has also applied for an audit from SGS to inspect the Helsinn sites in relation to the Occupational Health and Safety Assessment Series (OHSAS) 18001 ...
Amsterdam, Netherlands (ots/PRNewswire) - - XML Content Management System at Heart of New User-Centric Solution That Brings Consistency to Technical Documents Across 100s of Medical Products Astoria Software, the leading provider of XML content management solutions, today announced that Siemens Medical ...
Cranberry Township, Pennsylvania (ots/PRNewswire) - Three Rivers Pharmaceuticals, LLC announced today that it has completed the acquisition of worldwide ownership of Amphotec(R)/Amphocil(R) (amphotericin B cholesteryl sulfate complex for injection) from InterMune, Inc. (Nasdaq: ITMN). Amphotec is indicated for the treatment of invasive aspergillosis, a fungal ...
Princeton, New Jersey (ots/PRNewswire) - - BioWa Grants the Second Potelligent(TM) Antibody Technology License to Medarex BioWa, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent(TM) Technology for the enhancement of ...
Los Angeles (ots/PRNewswire) - Infotrieve, Inc. announced today the immediate availability of the company's Life Science Research Center(TM) (LSRC), a web-based information research tool that provides scientists with one-stop search access to critical information that impacts scientific workflow. The LSRC was designed to simplify research by eliminating the need for logins to multiple information sources including ...
Indianapolis (ots/PRNewswire) - - Europe's only approved non-stimulant ADHD medication offers a new treatment choice Eli Lilly and Company's Strattera(R), the only approved non-stimulant medication proven clinically effective(1) at treating the potentially serious symptoms of ...
Orlando, Florida (ots/PRNewswire) - - Landmark Study Big 1-98 Shows Letrozole Offers Greater Protection from Recurrence of Early Breast Cancer than Tamoxifen - Web Cast Briefing Available at 17 May 2005 8:00 AM EDT http://www.ibcsg.org/index.shtm Newly updated results of the independent Breast International Group 1-98 trial just released at ASCO show ...
Orlando, Florida (ots/PRNewswire) - - New Results Presented at ASCO Results from five clinical studies of YONDELIS (TM) (trabectedin) were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), in Orlando, Florida, from 13-17 May 2005. YONDELIS is being developed by PharmaMar ...
Basel, Switzerland (ots/PRNewswire) - The addition of Tarceva(tm) (erlotinib) to chemotherapy extends survival by 23.5% for patients with advanced pancreatic cancer, according to data presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, USA.(1) Tarceva, an advanced new cancer drug taken as a once-daily tablet, has already demonstrated a clear survival benefit for patients with ...
Basel, Switzerland (ots/PRNewswire) - - Anti-Angiogenic Treatment Shows Survival Benefit Across Three Major Cancer Types: Breast, Lung And Colorectal Cancer A new study with Avastin(R) (bevacizumab, rhuMAb-VEGF) today reported that when used in combination with chemotherapy, Avastin doubled the chances of ...
Basel, Switzerland (ots/PRNewswire) - - Addition of Avastin Boosts Efficacy of First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer A new study, presented for the first time today, reveals that Avastin(R) (bevacizumab rhuMAb-VEGF) significantly extends survival for patients with previously untreated, advanced non-small cell lung cancer (NSCLC), ...
Milan, Italy (ots/PRNewswire) - - Net Revenues Grow to 179.3 Million Euros in the First Quarter of 2005, or 1.8% More Than in the Same Period Last Year.(1) - EBITDA Total 16.5 Million Euros, Compared With 18.2 Million Euros in 2004, Improving 5.1% vs. Same Period Last Year (net of Exceptional Items of 2.5 ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has received permission from the Food and Drug Administration of the United States to proceed with a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. The planned randomized, open-label trial will include approximately 332 de novo (newly ...
Kyoto, Japan (ots/PRNewswire) - Omron Corporation announced today that it will acquire all shares of Colin Medical Technology Corporation (CMT) (Komaki, Japan) from Carlyle Group (Washington D.C.) and other stockholders through its wholly owned company, Omron Healthcare Co., Ltd. (Kyoto, Japan). The acquisition is planned for June 2005. Through this acquisition, ...
Montreal, Canada (ots/PRNewswire) - Genizon BioSciences, Inc., a Montreal-based gene and drug target discovery company, announced today it has acquired the majority of the assets and staff of Sweden-based Global Genomics AB. Through this transaction, Genizon has gained access to a novel sequencing technology, ...
Ecublens/Lausanne (ots) - AC Immune, a Swiss biotech company developing innovative therapies against Alzheimer's disease, today announced that it has successfully completed its round B financing raising CHF 21 million from private and strategic investors. The financing goal of CHF 21 millions was achieved with 2/3 of the invested capital contributed by new investors. AC immune is focused on new therapies for the ...
Espoo, Finland (ots/PRNewswire) - Net sales of the Orion Group were EUR 465.3 (496.9) million, down by 6.4% due to decreased invoicing of the pharmaceutical distribution business. Group operating profit grew by 52.2% to EUR 50.8 (33.4) million, thanks to the favourable performance of Orion Pharma. Group profit before taxes was EUR 50.6 (33.0) million. Earnings per share were EUR 0.27 (0.17). Equity ratio was 40.7% ...
New York (ots/PRNewswire) - The VIP goodie bag company, Madison & Mulholland (M|M) created a limited edition of 50 goodie bags for the American Pavilion 2005 Cannes Film Festival. As word got out about this hot US$4000 goodie bag, phones have started ringing off the hook. Jane Ubell-Meyer, M|M's president, "In four years of creating VIP goodie bags, this is the ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company will web cast its Annual General Meeting in Toronto on Tuesday, May 10, 2005 at 10:00 a.m. EDT. The web cast will include corporate and scientific updates. The web cast will be chaired by Dr. Robert Foster, Chairman and CEO; with Dr. Randall Yatscoff, President and COO presenting the scientific update. Interested parties can ...
Markham, Canada (ots/PRNewswire) - Cytochroma Inc. announced today that the Company has received the first tranche of a CDN $15 million financing. The funds will be used by Cytochroma to continue advancement of CTA018 towards a Phase II clinical trial for psoriasis as well as to extend its pipeline of late-stage preclinical products. This recent round of financing was led by VenGrowth Private Equity Partners Inc. ...
Amsterdam, Netherlands (ots/PRNewswire) - - Hospira Healthcare B.V. will also serve as regional headquarters for Europe, Middle East and Africa -- Today Hospira, Inc. (pronounced Hos-PEER-ah), a global independent specialty pharmaceutical and medication delivery company created in April 2004 from the core global hospital products business of Abbott Laboratories, announced that it has established its presence ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247. This randomized, open-label trial will include approximately 332 de novo (newly transplanted) kidney patients. Patients ...
Madrid (ots/PRNewswire) - PharmaMar: - Zalypsis: this is PharmaMar's fifth compound to reach clinical development. - Aplidin: commenced Phase II studies on prostate and bladder cancer. - Yondelis: pivotal Phase III studies commenced on ovarian cancer patients. NeuroPharma: - Presented pre-clinical data at the 7th International Conference on Alzheimer's and Parkinson's Disease. Other: - ...
Lugano, Switzerland, and Ljulubiana (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and PHARMASWISS, a Pharmaceutical company based in SLOVENIA, announce the signing of an agreement granting PHARMASWISS the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to show promising results. The Canadian Phase III Psoriasis trial (SPIRIT) which commenced on December 2, 2004, includes a total of 453 patients with stable moderate to severe plaque psoriasis. The trial is currently being conducted in 32 sites and ...
New Brunswick, New Jersey and Indianapolis (ots/PRNewswire) - Johnson & Johnson and Guidant Corporation today announced that they have been notified, as anticipated, that the European Commission has decided to open a second phase review into the proposed acquisition of Guidant by Johnson & Johnson. The companies ...
Montreal, Canada (ots/PRNewswire) - Genizon BioSciences today announced the confirmation of a previously reported disease-gene location, PSORS1, as well as the identification of more than 10 new regions strongly associated with psoriasis, each containing only a limited number of genes. The company will be discussing with potential pharmaceutical partners how ...
New York (ots/PRNewswire) - Genesis Bioventures, Inc. (AMEX:GBI) (GBI) today reported that its Annual Report on Form 10-KSB for the year ended December 31, 2004 was not filed by the deadline of Friday, April 15, 2005. The Company expects to file the 2004 annual report on or before May 15, 2005. GBI explained that the delay in filing was caused by the termination ...